Business Context and Reporting Period
Catheter Precision, Inc. (VTAK) filed a Form 8-K on February 6, 2026, reporting the entry into material definitive agreements for a private placement financing and a strategic acquisition. The company, incorporated in Delaware, is currently engaged in restructuring its legacy catheter business while pivoting toward new ventures.
Key Financial Metrics and Capital Structure
The filing details a complex capital raise and asset acquisition rather than standard operating financials. Key figures include:
- Initial Financing Proceeds: Expected gross proceeds of $2,177,759 from the sale of 392,608 Common Shares and 1,616.33 Series C-1 Convertible Preferred Shares.
- Potential Additional Financing: Agreements to purchase up to $3,232,660 in Series C-2 and C-3 Preferred Stock, and up to $39,233,333 in Series C-4 Preferred Stock, subject to closing conditions.
- Acquisition Cost: $5.25 million in Series D Convertible Preferred Stock to acquire a 19.98% stake in Fly Flyte, Inc. (FLYTE).
- Warrant Exercise Proceeds: $400,621.04 expected from the exercise of existing warrants by Series B holders at a reduced price.
- Placement Agent Fees: 7.7% cash fee on proceeds exceeding $3,850,000; no fee on the first $3.85 million.
The filing does not provide current revenue, profit, cash flow, or debt levels, as this is a transactional report.
Material Changes and Strategic Shifts
The company is executing a significant strategic pivot:
- Business Restructuring: Proceeds are designated to unwind, wind down, divest, or restructure the legacy catheter business, potentially including a going-private transaction, spin-off, or wholesale shutdown.
- New Venture Acquisition: The company is acquiring a 19.98% interest in FLYTE, a luxury regional air-mobility company utilizing AI-driven operations and Vision Jets.
- Capital Structure Simplification: The financing aims to resolve legacy liabilities and simplify the balance sheet.
- Stockholder Approval Requirement: Future closings and conversions are contingent on stockholder approval for a reverse stock split (ratio 1-for-2 to 1-for-100) and the issuance of shares exceeding 19.99% of outstanding common stock.
Outlook, Risks, and Contingencies
Management's outlook is tied to the successful closing of the financing and the restructuring plan.
- Closing Conditions: The "First Closing" is expected around February 9, 2026. Subsequent closings for Series C-2, C-3, and the FLYTE acquisition depend on stockholder approval and, for Series C-3, the effectiveness of an SEC registration statement.
- Conversion Price Risks: Preferred stock conversion prices are subject to downward adjustments based on market prices (80% of applicable price) and a "Floor Price Condition" of $0.35, which the company may waive at its sole discretion.
- Use of Proceeds: Primary use is debt repayment, followed by general corporate purposes and funding the restructuring of the legacy business.
- Regulatory Timeline: The company must file a registration statement within 30 days of the First Closing and seek effectiveness within 60 days (or 120 days if a full review is required).
Investor Verification Checklist
- Verify the outcome of the stockholder meeting required within 60 days of the First Closing to approve the reverse stock split and share issuance.
- Confirm the actual closing date and final proceeds of the First Closing versus the expected $2.18 million.
- Monitor the effectiveness of the SEC registration statement required for the resale of underlying common stock.
- Assess the specific terms of the "Floor Price Condition" waiver and its potential impact on existing shareholder dilution.
- Review the detailed restructuring plan for the legacy catheter business to understand the timeline for wind-down or divestiture.